Pancreatic Cancer Research

ResearcherGuangdong Academy of Medical SciencesActive in the last 2 years

Rihua He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-0512-6806; OpenAlex author ID A5044164561. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 6 papers · 2026: 3 papers

Papers 14

  1. circMTHFD1L-driven lipid metabolism in Cancer-associated fibroblasts confers oxaliplatin resistance in pancreatic cancer through O-GlcNAcylation-dependent chro… Co-author DOI 10.1016/j.canlet.2026.218863↗
  2. circFOXP1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Regulating EREG/MAPK/ERK Axis. Co-author DOI 10.1111/jcmm.71230↗
  3. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. Co-author DOI 10.7150/thno.122294↗
  4. Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation. Co-author DOI 10.1038/s41419-025-07431-4↗
  5. Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank. Co-author DOI 10.1136/bmjgast-2025-001870↗
  6. Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3173↗
  7. N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-025-03362-2↗
  8. Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis. First author DOI 10.1186/s13046-025-03489-2↗
  9. Unexpected complete remission after recurrence in pancreatic cancer: a case report on comprehensive multimodal therapy. Last author DOI 10.3389/fonc.2025.1582673↗
  10. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Co-author DOI 10.1126/scitranslmed.adi0178↗
  11. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  12. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. Co-author DOI 10.3892/ijo.2023.5493↗
  13. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Co-author DOI 10.1038/s41388-022-02253-6↗
  14. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 12 shared papers, 2022–2026 · strength 2.48
  2. Chonghui Hu · 8 shared papers, 2022–2026 · strength 1.58
  3. Huimou Chen · 6 shared papers, 2025–2026 · strength 1.42
  4. Tianhao Huang · 5 shared papers, 2024–2026 · strength 1.14
  5. Rufu Chen · 5 shared papers, 2024–2026 · strength 1.11
  6. Chengyuan Hu · 5 shared papers, 2024–2025 · strength 1.11
  7. Quanbo Zhou · 3 shared papers, 2022–2026 · strength 0.67
  8. Yu Zhou · 3 shared papers, 2023–2026 · strength 0.64
  9. Rufu Chen · 3 shared papers, 2023–2025 · strength 0.64
  10. Zhiqiang Fu · 3 shared papers, 2023–2025 · strength 0.64
  11. Renpeng Xia · 4 shared papers, 2022–2023 · strength 0.63
  12. Guolin Li · 3 shared papers, 2022–2025 · strength 0.56
  13. Leyi Huang · 2 shared papers, 2025–2026 · strength 0.53
  14. Rufu Chen · 3 shared papers, 2022–2025 · strength 0.52
  15. Yong Jiang · 2 shared papers, 2025–2026 · strength 0.46
  16. Tingting Li · 2 shared papers, 2025 · strength 0.46
  17. Yuan Yuan · 2 shared papers, 2025 · strength 0.43
  18. Yu Zhou · 2 shared papers, 2024–2025 · strength 0.41
  19. Zhihua Li · 2 shared papers, 2022–2026 · strength 0.39
  20. Xiang Zhang · 2 shared papers, 2022–2024 · strength 0.33
  21. Xiang Zhang · 2 shared papers, 2022–2023 · strength 0.33
  22. Dan Su · 1 shared paper, 2026 · strength 0.29
  23. Xiaofeng Guo · 1 shared paper, 2026 · strength 0.29
  24. Tian Qing · 1 shared paper, 2026 · strength 0.25
  25. Rufu Chen · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.